Oligopeptide-68 (marketed as B-White by Sederma) is a synthetic peptide designed to inhibit melanin biosynthesis at both the enzymatic and transcriptional levels. It targets tyrosinase -- the rate-limiting enzyme in melanin production -- and reduces expression of MITF (microphthalmia-associated transcription factor), the master transcriptional regulator of melanocyte differentiation and pigmentation.

Overview

Melanin biosynthesis is a multi-step enzymatic process within melanosomes that converts L-tyrosine to melanin polymers. Tyrosinase catalyzes the first two steps: hydroxylation of L-tyrosine to L-DOPA and oxidation of L-DOPA to dopaquinone. The expression and activity of tyrosinase are controlled by the transcription factor MITF, which is itself regulated by multiple upstream signaling pathways including MC1R/cAMP/CREB, SCF/c-Kit/MAPK, and Wnt/beta-catenin.

Oligopeptide-68 intervenes in this regulatory network at two critical points: it directly inhibits tyrosinase enzymatic activity, and it suppresses MITF expression, thereby reducing transcription of tyrosinase and other melanogenic enzymes (TRP-1, TRP-2/DCT). This dual mechanism provides more potent and sustained melanogenesis inhibition than agents targeting only one step.

The peptide was developed by Sederma as a cosmetic active ingredient and is found in numerous professional and consumer skin brightening products marketed globally. Clinical data from Sederma demonstrate significant reductions in melanin content and visible improvement in skin evenness and luminosity.

Mechanism of Action

Tyrosinase Inhibition

Oligopeptide-68 binds to the active site of tyrosinase, competing with L-tyrosine and L-DOPA substrates for access to the copper-containing catalytic center. This competitive inhibition reduces the rate of dopaquinone formation, the committed step in melanin biosynthesis. Unlike kojic acid (which chelates copper from the tyrosinase active site) or hydroquinone (which acts as an alternative substrate producing toxic metabolites), oligopeptide-68 inhibits tyrosinase through peptide-protein interaction without generating cytotoxic byproducts.

MITF Suppression

MITF is the master regulator of melanocyte biology, controlling expression of tyrosinase, TRP-1, TRP-2/DCT, PMEL17, and other genes essential for melanin synthesis, melanosome biogenesis, and melanocyte survival. Oligopeptide-68 reduces MITF protein levels through modulation of upstream signaling, leading to decreased transcription of the entire melanogenic gene program.

Sederma's published data show that oligopeptide-68 treatment reduces MITF expression in melanocyte cultures by approximately 47% at optimal concentrations. This transcriptional effect amplifies the direct enzymatic inhibition, as reduced MITF leads to lower steady-state levels of tyrosinase protein over time.

Melanosome Maturation Inhibition

By reducing both tyrosinase activity and MITF-driven melanogenic gene expression, oligopeptide-68 impairs melanosome maturation. Melanosomes progress through four stages (I-IV), with melanin deposition occurring primarily in stages III and IV. Oligopeptide-68-treated melanocytes show accumulation of stage I-II melanosomes with reduced progression to heavily melanized stage III-IV organelles, resulting in lower total melanin content per cell.

Anti-Inflammatory Pathway

Oligopeptide-68 also exhibits anti-inflammatory activity relevant to post-inflammatory hyperpigmentation (PIH). It reduces production of prostaglandin E2 (PGE2) and endothelin-1 (ET-1) by keratinocytes -- two paracrine factors that stimulate melanogenesis independent of the alpha-MSH/MC1R pathway. This anti-inflammatory mechanism makes oligopeptide-68 particularly effective for PIH, where inflammation-driven melanogenesis predominates.

Reconstitution Calculator

Research

Safety Profile

Oligopeptide-68 has an excellent safety profile consistent with cosmetic peptide ingredients. Sederma's safety data demonstrate that the peptide is non-irritating, non-sensitizing, and non-phototoxic at recommended use concentrations (0.001-0.01%). Patch testing in human volunteers shows no adverse reactions. The peptide does not damage melanocytes or keratinocytes -- melanogenesis inhibition is fully reversible upon discontinuation. Unlike hydroquinone, oligopeptide-68 does not produce cytotoxic quinone metabolites and carries no risk of exogenous ochronosis. The peptide is stable in cosmetic formulations at pH 4-7 and is compatible with common cosmetic ingredients. As a topical ingredient, systemic absorption is negligible. It is considered safe for all skin types, including Fitzpatrick types IV-VI, where aggressive depigmenting agents carry higher risk of rebound hyperpigmentation.

Pharmacokinetic Profile